regulatori data catalyst
jakafi revenu revenu in-lin consensu
respect patient demand jakafi remain strong
grow sale y-o-i product royalti jakavi
grow y-o-i olumi royalti grown sinc launch
contribut top-lin non-gaap oper profit record
benefit non-gaap total product-rel revenu growth
versu non-gaap expens growth y-o-i revenu guidanc jakafi
iclusig well expens guidanc gener in-lin consensu
updat estim maintain buy rate po
improv oper margin increas success probabl earli pipelin asset
jakafi see volum growth gvhd upsid
jakafi continu primari contributor inci top-lin us sale jakafi
grew y-o-i driven growth myelofibrosi mf polycythemia
vera pv mf pv compris sale respect spontan
off-label use graft-versus-host diseas gvhd also ad roughli sale
could doubl follow offici fda approv launch prepar well
underway higher gross-to-net adjust driven increas govern payer
rebat higher discount medicar part coverag gap donut hole
also expect therefor project sale growth jakafi continu
driven volum increas
multipl regulatori data catalyst expect
six late-stag product target indic oncolog hematolog
may pdufa data set jakafi steroid-refractori acut gvhd nda
submiss pemigatinib cholangiocarcinoma capmatinib novarti
partner non-smal cell lung cancer nsclc expect data readout
phase pemigatinib bladder cancer phase ruxolitinib cream vitiligo
phase jakafi sr-cgvhd phase itacitinib sn-agvhd expect
encourag data-to-d program await pivot
data complet assess substanc inci late-stag pipelin
net dbt
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biotechnolog compani focus drug
develop hematology/oncolog
inflamm multipl market product
includ inhibitor jakafi approv
myelofibrosi polycythemia vera olumi
baricitinib approv ra eu us
iclusig cml emerg rich clinic
rate share buy see signific
valu market product jakafi ruxolitinib
mf pv see signific potenti
compani robust pipelin olumi
approv eu us ruxolitinib gvhd ad
fgfr inhibitor liquid solid
po deriv probability-adjust npv analysi includ
jakafi call jakavi ex-u mf pv jakafi/itacitnib gvhd
baricitinib iclusig pemigatinib
ruxolitinib cream earli pipelin asset also includ approx
net cash use wacc termin valu
downsid risk price object weaker-than-expect sale jakafi mf
pv unfavor efficaci and/or safeti data pipelin asset clinic trial
earlier-than-expect more-than-expect competit jakafi approv
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
